Cunningham joins MacuSight board of directors

December 1, 2006

Union City, CA-MacuSight Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, announced the appointment of Brian C. Cunningham to its board of directors.

Union City, CA-MacuSight Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, announced the appointment of Brian C. Cunningham to its board of directors.

Cunningham presently serves as chief executive officer of DaoGen Inc. and Clerigen Inc., both early stage biopharmaceutical companies, and is of counsel to Cooley Godward Kronish LLP in its business department. In addition, Cunningham is a director of Synarc Inc., a private, imaging-based clinical research organization.

Related Content:

Pharmacy